Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−2.24 EUR
−695.17 M EUR
2.87 B EUR
238.79 M
About BioNTech SE Sponsored ADR
Sector
Industry
CEO
Ugur Sahin
Website
Headquarters
Mainz
Founded
2008
IPO date
Oct 10, 2019
Identifiers
3
ISIN US09075V1026
BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.
Related stocks
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
